Patients With Overweight or Obesity Show Significant Weight Loss in Phase 2 Survodutide Trial
After receiving 4.8 mg of survodutide weekly for 46 weeks, more than half of trial participants achieved weight loss of 15% or more.
Related Articles
Dr Darius Lakdawalla Previews the ISPOR 2024 Conference
Darius Lakdawalla, PhD, director of research, Schaeffer Center for Health Policy & Economics at the University of Southern California, discusses the growing importance of value…
Impact of IRA Seen as ISPOR 2024 Heads to Atlanta
About 5000 leaders in health economics and outcomes research will gather for the 2024 meeting, which has the theme, “HEOR: A Transformative Force for Whole Health.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total…
What We’re Reading: Bird Flu Vaccines; Walmart Health Shut Down; Arizona Repeals Abortion Ban
Two bird flu vaccines could be available within weeks; Walmart Health struggles to expand in retail health care services; repeal of 1864 law preserves abortion…
What We’re Reading: FTC Challenges Drugmaker Patents; Testing Ground Beef for Bird Flu; Rural Americans at Higher Early Death Risk
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture…
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for…
How Well Do You Know the April Issue of AJMC?
Test your knowledge of the April 2024 issue of AJMC with a quick quiz!
Tackling Health Inequality: The Power of Education and Experience
To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health…
Dr Michael Morse on Managing Toxicities During HCC Treatment
Michael Morse, MD, FACP, MHS, medical oncologist at Duke Cancer Center, explained the importance of managing toxicities in the changing hepatocellular carcinoma (HCC) treatment landscape…
Competition From Skinny-Label Generics Saved Medicare Nearly $15B Over 5 Years
A new court ruling has the future use of skinny labels in question, but skinny-label generics have saved Medicare a lot of money over 5…